Similarly, the analysis results obtained by Hellmann MD et al. attested that first-line treatment with nivolumab plus ipilimumab provided clinical benefits for patients with NSCLC and a high TMB (≥10 mutations per megabase), regardless of their tumor PD-L1 expression levels (18). This evidence concerns the gene CD274 and neoplasm.